What is BrightGene Bio-Medical Technology Co., Ltd.'s (688166.SS) StockRank?

MoatMap's StockRank for BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) is 11/100, with a Strong Sell signal. This is a composite score combining Quality (43), Value (11), and Momentum (42) factor ranks across MoatMap's 20,000+ stock universe.

Does BrightGene Bio-Medical Technology Co., Ltd. have an economic moat?

BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is BrightGene Bio-Medical Technology Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is BrightGene Bio-Medical Technology Co., Ltd. in?

BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688166.SS

STRONG SELLREMOVE

BrightGene Bio-Medical Technology Co., Ltd. · Healthcare · China · $3.3B · Avg Vol: $73M/d

StockRank

P/E (TTM)

350.4x

ROE

1.9%

D/E

1.1x

Dividend %

0.0%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

BrightGene is primarily an API and generic drug developer rather than a high-moat biologics CDMO. It lacks the proprietary platform scale and regulatory lock-in required to benefit from the advanced CDMO pricing power cycle, leaving it exposed to domestic Chinese price volume controls.

COMPANY DESCRIPTION

BrightGene Bio-Medical Technology Co., Ltd. develops and manufactures high-barrier active pharmaceutical ingredients (APIs) and finished dosage forms, focusing on oncology and anti-infectives. The company's competitive moat is driven by its advanced synthetic biology and fermentation platforms, which enable the production of highly complex, difficult-to-synthesize generic drugs. It is a technology-driven specialty pharmaceutical player with a global commercialization footprint.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	150M	174M	190M	181M	6.3%
EPS	0.09	0.07	0.07	0.02	-39.3%
Shares	422M	422M	422M	423M	+0.2%
Debt	299M	326M	329M	348M	5.2%
Equity	324M	350M	352M	373M	4.8%
Op CF	46M	29M	36M	48M	1.5%
Inv CF	-129M	-65M	-65M	-92M	—
Fin CF	202M	9M	-4M	74M	—

PRICE (1M)-34.7%

SMA 50SMA 200

$6.43

RSI (14)

27.3

52W High

$18.11

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

1.7%47.7

ROE

1.9%48.3

GP/Assets

11.8%29.2

Op. Margin

3.6%51.7

FCF/Assets

-5.5%35.0

Piotroski

—83.4

Int. Cover

1.2x42.6

D/E Ratio

1.06x13.9

Current Ratio

2.33x43.6

Value

P/E (TTM)

350.4x2.7

EV/EBITDA

93.6x3.4

P/FCF

—N/A

P/B

7.0x16.7

P/S

14.1x20.8

Div Yield

0.0%2.6

Momentum

52W High %

36%9.3

RS 6M

-26%49.2

SMA 50/200

0.95x48.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—94.2

Q Growth

-28%19.2

FUNDAMENTALS

Market Cap

$3.3B

P/E (Forward)

71.3x

Gross Margin

52.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688166.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688166.SS	BrightGene Bio-Medical Technology Co., Ltd.(you)	$3.3B	11	STRONG SELL
9606.HK	Duality Biotherapeutics, Inc.	$2.6B	11	STRONG SELL
688520.SS	Sinocelltech Group Limited	$2.7B	8	STRONG SELL
7666.HK	METIS TECHBIO-P	$2.2B	7	STRONG SELL
1877.HK	Shanghai Junshi Biosciences Co., Ltd.	$2.8B	21	SELL
688382.SS	InventisBio Co., Limited	$1.7B	12	STRONG SELL
300255.SZ	Hebei Changshan Biochemical Pharmaceutical Co., Ltd.	$5.6B	6	STRONG SELL
300204.SZ	Staidson (Beijing) BioPharmaceuticals Co., Ltd.	$1.8B	15	STRONG SELL
2616.HK	CStone Pharmaceuticals	$1.6B	14	STRONG SELL
688062.SS	Mabwell (Shanghai) Bioscience Co., Ltd.	$2.0B	3	STRONG SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) — Stock Score Summary

BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) has a MoatMap StockRank of 11/100 based on Quality (43/100), Value (11/100), and Momentum (42/100) factor scores. The current signal is STRONG SELL. BrightGene is primarily an API and generic drug developer rather than a high-moat biologics CDMO. It lacks the proprietary platform scale and regulatory lock-in required to benefit from the advanced CDMO pricing power cycle, leaving it exposed to domestic Chinese price volume controls.

Key Financial Metrics

Price	$6.43
Market Cap	$3.3B
P/E (TTM)	350.42
P/E (Forward)	71.27
Price/Book	7.02
Return on Equity	1.9%
Return on Invested Capital	1.7%
Debt/Equity	106.46
Gross Margin	52.6%
Operating Margin	3.6%
Revenue Growth	30.5%
Dividend Yield	0.0%
Free Cash Flow	$-7M

BrightGene Bio-Medical Technology Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is BrightGene Bio-Medical Technology Co., Ltd.’s (688166.SS) StockRank?: MoatMap’s StockRank for BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) is 11/100, with a Strong Sell signal. It is a composite of Quality (43), Value (11), and Momentum (42) factor ranks across MoatMap’s 20,000+ stock universe.
Does BrightGene Bio-Medical Technology Co., Ltd. have an economic moat?: BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BrightGene Bio-Medical Technology Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BrightGene Bio-Medical Technology Co., Ltd. in?: BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).